This executive order seeks to operationalize the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR), a stockpile created during the first Trump administration to reduce American dependence on foreign sources for essential medicines. The order characterizes the Biden administration's pharmaceutical supply chain efforts as a failure, claiming that despite billions in spending, domestic production did not increase and the SAPIR remains "nearly empty." Building on Executive Order 13944 from August 2020, the order emphasizes that while nearly two in five prescription finished drug products are manufactured domestically, only approximately 10 percent of Active Pharmaceutical Ingredients (APIs)—the biologically active components of drugs—are produced in the United States by volume. The order frames this dependence as a national security concern, particularly regarding concentration of API production in foreign and potentially adversarial nations. Critically, the order relies entirely on repurposing existing available funds through OMB assistance and does not create new appropriations, invoke Defense Production Act authorities, or establish binding domestic content mandates. The domestic preference for API procurement is explicitly conditional—"if possible"—meaning APIs may be sourced from abroad if domestic supply is unavailable or cost-prohibitive, which materially affects the extent to which this action advances reshoring versus short-term stockpiling.
The order establishes specific mechanisms and timelines centered on stockpiling rather than structural capacity expansion. Within 30 days, the Office of the Assistant Secretary for Preparedness and Response (ASPR) must develop a list of approximately 26 "critical drugs" essential to national health and security interests, though the order provides no explicit selection criteria such as clinical criticality, single-source vulnerabilities, geopolitical concentration risks, shortage history, or surge demand scenarios. This undefined framework means senior leaders cannot assess whether the SAPIR will meaningfully cover the most consequential vulnerabilities or which national security and public health risks will actually be mitigated. Within 120 days, ASPR must ready the existing SAPIR repository to receive and maintain APIs, subject to fund availability. The order directs ASPR to obtain a 6-month supply of APIs for the critical drugs and place them in the repository within 30 days of certification. Additionally, within 90 days, ASPR must update its 2022 list of 86 essential medicines and provide a plan to obtain, store, and maintain a 6-month supply of APIs for drugs not covered by the critical drugs list, including a proposal and cost estimate for opening a second SAPIR repository within one year.
Implementation responsibility falls primarily to ASPR within the Department of Health and Human Services, with coordination from the Assistant to the President for Economic Policy, the Assistant to the President and Homeland Security Advisor, and the Office of Management and Budget. The order's core instrument is stockpiling finished APIs rather than establishing sustained domestic production capacity through long-term demand signals such as multi-year offtake agreements, advance market commitments, or tax incentives. The order does not address key starting materials and advanced intermediates that underpin API production, potentially leaving upstream vulnerabilities unaddressed and limiting long-term resilience implications. All actions are subject to the availability of appropriations and must be implemented consistent with applicable law. The staggered implementation timeline spans from 30 days for initial planning to one year for the potential second repository, with the critical 6-month API supply to be stockpiled within approximately 150 days, assuming funds are identified and the repository is prepared on schedule.